Literature DB >> 12007946

Predictive factors of urinary retention following prostate brachytherapy.

Joseph Bucci1, W James Morris, Mira Keyes, Ingrid Spadinger, Sabeena Sidhu, Veronika Moravan.   

Abstract

PURPOSE: To evaluate the incidence and duration of urinary retention requiring catheterization and the factors predictive for these end points. METHODS AND MATERIALS: Two hundred eighty-two patients treated with prostate brachytherapy alone were evaluated. Clinical and treatment-related factors examined included: age, baseline International Prostate Symptom Score (IPSS), presence of comorbidity, planning ultrasound target volume (PUTV), postimplant prostate CT scan volume, the CT:PUTV ratio, number of seeds inserted, number of needles used, use of neoadjuvant hormones, procedural physician, clinical stage, Gleason score, and pretreatment PSA. Dosimetric quality indicators were also examined.
RESULTS: Urinary obstruction after prostate brachytherapy developed in 43 (15%) patients. The median duration of catheter insertion was 21 days (mean 49, range 1-365). Univariate analysis demonstrated that presence of diabetes, preimplant volume, postimplant volume, CT:PUTV ratio, number of needles, and dosimetric parameters were predictive for catheterization. However, in multivariate analysis, only the baseline IPSS, CT:PUTV ratio, and presence of diabetes were significant independent predictive factors for catheterization.
CONCLUSION: Baseline IPSS was the most important predictive factor for postimplantation catheterization. The extent of postimplant edema, as reflected by the CT:PUTV ratio, predicted for need and duration of catheterization. The presence of diabetes was predictive for catheterization, but may relate to the absence of prophylactic steroids, and therefore requires further evaluation.

Entities:  

Mesh:

Year:  2002        PMID: 12007946     DOI: 10.1016/s0360-3016(01)02812-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Acute urinary morbidity following I-125 prostate brachytherapy.

Authors:  Toshio Ohashi; Atsunori Yorozu; Kazuhito Toya; Shiro Saito; Tetsuo Momma
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

2.  Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.

Authors:  V Morillo; J L Guinot; I Tortajada; J V Ricós; L Arribas; M Maroñas; M Estornell; J Casanova
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

3.  Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.

Authors:  Nobutaka Shimizu; Takafumi Minami; Koichi Sugimoto; Yoshitaka Saito; Yutaka Yamamoto; Taiji Hayashi; Hidenori Tsuji; Masahiro Nozawa; Kazuhiro Yoshimura; Tokumi Ishii; Hirotsugu Uemura; Kiyoshi Nakamatsu
Journal:  World J Urol       Date:  2014-01-17       Impact factor: 4.226

4.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Authors:  Omid C Farokhzad; Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Sangyong Jon; Philip W Kantoff; Jerome P Richie; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

Review 5.  [Curative radiotherapy of localized prostate cancer. Treatment methods and results].

Authors:  R Schwarz
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 6.  Brachytherapy with permanent seed implantation.

Authors:  Shiro Saito; Hirohiko Nagata; Michio Kosugi; Kazuhito Toya; Atsunori Yorozu
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 7.  What's a man to do? Treatment options for localized prostate cancer.

Authors:  Tom Pickles
Journal:  Can Fam Physician       Date:  2004-01       Impact factor: 3.275

8.  Prostate volume changes during permanent seed brachytherapy: an analysis of intra-operative variations, predictive factors and clinical implication.

Authors:  Ciprian Chira; Guila Delouya; Sandra Larrivée; Jean-Francois Carrier; Daniel Taussky
Journal:  Radiat Oncol       Date:  2013-07-09       Impact factor: 3.481

9.  Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.

Authors:  W Tristram Arscott; Leonard N Chen; Nathan Wilson; Aditi Bhagat; Joy S Kim; Rudy A Moures; Thomas M Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2014-07-24       Impact factor: 3.481

10.  Comparison of two treatment approaches for prostate cancer: intensity-modulated radiation therapy combined with 125I seed-implant brachytherapy or 125I seed-implant brachytherapy alone.

Authors:  Yulin Song; Maria F Chan; Chandra Burman; Donald Cann
Journal:  J Appl Clin Med Phys       Date:  2008-03-18       Impact factor: 2.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.